Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/- Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone

被引：7

作者：

Boehrer, Simone ^{[1
]}

Beyne-Rauzy, Odile ^{[2
]}

Prebet, Thomas ^{[3
]}

Park, Sophie ^{[4
]}

Guerci, Agnes ^{[5
]}

Stamatoulas, Aspasia ^{[6
]}

Chaury, M. P. ^{[7
]}

Jernival, Tony ^{[1
]}

Sanhes, Laurence ^{[8
]}

Tertian, Gerard ^{[9
]}

Cheze, Stephane ^{[10
]}

Lim, Eng-Mong ^{[11
]}

Choufi, Bachra ^{[12
]}

Caillot, Denis ^{[13
]}

Wattel, E. ^{[14
]}

Delaunay, Jacques ^{[15
]}

Legros, Laurence ^{[16
]}

Chermat, Fatiha ^{[17
]}

Isnard, Francoise ^{[18
]}

Cambier, N. ^{[19
]}

Slama, Borhane ^{[20
]}

Roy, Lydia ^{[21
]}

Damaj, Gandhi ^{[22
]}

Raffoux, Emmanuel ^{[23
]}

Dreyfus, Francois ^{[24
]}

Recher, Christian ^{[25
]}

Vey, Norbert ^{[26
]}

Chevret, Sylvie ^{[23
]}

Fenaux, Pierre ^{[27
]}

Gardin, Claude ^{[11
]}

机构：

[1] Univ Paris 13, Hop Avicenne, APHP, Bobigny, France

[2] Hop Purpan, Toulouse, France

[3] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France

[4] Univ Paris 05, Hop Cochin, Serv Hematol, Paris, France

[5] CHU Nancy, Nancy, France

[6] Ctr Henri Becquerel, Dept Hematol, F-76038 Rouen, France

[7] CHRU Limoges, Limoges, France

[8] Hop Hotel Dieu, INSERM, E0355, Paris, France

[9] Hop Bicetre, Caen, France

[10] CHU Clemenceau, Serv Hematol Clin, Caen, France

[11] Hop Avicenne, Serv Hematol Clin, F-93009 Bobigny, France

[12] Ctr Hosp Boulogne Mer, Boulogne, France

[13] CHU, Dijon, France

[14] Ctr Hosp Edouard Herriot, Lyon, France

[15] CHU Nantes, Dept Hematol, F-44035 Nantes 01, France

[16] Hop Archet, Serv Hematol, Nice, France

[17] GFM, Bobigny, France

[18] St Antoine Hosp, Paris, France

[19] Hop St Vincent de Paul, Lille, France

[20] CH Avignon, Avignon, France

[21] Univ Poitiers Hosp, Poitiers, France

[22] Univ Hosp CHU Sud, Amiens, France

[23] Hop St Louis, Paris, France

[24] Univ Paris 05, INSERM, Fac Med Rene Descartes, CNRS,U1016,UMR 8104,UM 3,Cochin Inst,Hematol Dept, F-75270 Paris, France

[25] CHU Purpan, Serv Hematol Clin, Toulouse, France

[26] Hop Paoli Calmettes, Marseille, France

[27] Univ Paris 13, Hop Avicenne, Serv Hematol Clin, Bobigny, France

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

10.1182/blood.V116.21.1880.1880

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：784 / 784

页数：1

共 50 条

[1] RESULTS OF A PHASE II TRIAL OF AZACITIDINE (AZA) plus /- EPOETIN BETA (EPO) IN LOWER RISK MDS
Gardin, C.
Thepot, S.
Beyne-Rauzy, O.
Prebet, T.
Park, S.
Stamatoullas, A.
Guerci, A.
Cheze, S.
Tertian, G.
Choufi, B.
Legros, L.
Bastie, J.
Delaunay, J.
Wattel, E.
Dreyfus, F.
Vey, N.
Boehrer, S.
Fenaux, P.
HAEMATOLOGICA, 2012, 97 : 361 - 361
[2] A randomized phase II trial of azacitidine plus /- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents
Thepot, Sylvain
Ben Abdelali, Raouf
Chevret, Sylvie
Renneville, Aline
Beyne-Rauzy, Odile
Prebet, Thomas
Park, Sophie
Stamatoullas, Aspasia
Guerci-Bresler, Agnes
Cheze, Stephane
Tertian, Gerard
Choufi, Bachra
Legros, Laurence
Bastie, Jean Noel
Delaunay, Jacques
Chaury, Marie Pierre
Sanhes, Laurence
Wattel, Eric
Dreyfus, Francois
Vey, Norbert
Chermat, Fatiha
Preudhomme, Claude
Fenaux, Pierre
Gardin, Claude
HAEMATOLOGICA, 2016, 101 (08) : 918 - 925
[3] Results of a phase II trial of azacitidine (AZA) with or without epoetin beta (EPO) in lower-risk MDS.
Gardin, Claude
Thepot, Sylvain
Beyne-Rauzy, Odile
Prebet, Thomas
Park, Sophie
Stamatoulas, Aspasia
Guerci-Bresler, Agnes
Cheze, Stephane
Tertian, Gerard
Choufi, B.
Legros, Laurence
Bastie, Jean Noel
Delaunay, Jacques
Wattel, Eric
Dreyfus, Francois
Vey, Norbert
Boehrer, Simone
Fenaux, Pierre
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[4] A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)
Guerra, Veronica A.
Kantarjian, Hagop M.
Cortes, Jorge E.
Garcia-Manero, Guillermo
Masarova, Lucia
Pemmaraju, Naveen
Jabbour, Elias
Kadia, Tapan M.
DiNardo, Courtney D.
Zhou, Lingsha
Pierce, Sherry A.
Borthakur, Gautam M.
Wierda, William G.
Ferrajoli, Alessandra
Sasaki, Koji
Takahashi, Koichi
Naqvi, Kiran
Alvarado, Yesid
Ohanian, Maro N.
Jain, Nitin
Bose, Prithviraj
Ravandi, Farhad
Konopleva, Marina Y.
Estrov, Zeev E.
Verstovsek, Srdan
Daver, Naval G.
BLOOD, 2019, 134
[5] Interim analysis of phase II randomized trial of azacitidine versus support treatment in patients with low-risk myelodysplastic syndrome
Sanchez-Garcia, J.
Falantes, J.
Medina, A.
Hernandez-Mohedo, F.
Torres-Sabariego, A.
Hermosin, L.
Bailen, A.
Sole, M.
Casano, J.
Calderon, C.
Vahi, M.
Serrano, J.
LEUKEMIA RESEARCH, 2013, 37 : S162 - S162
[6] A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS)
Garcia-Manero, Guillermo
Berdeja, Jesus G.
Komrokji, Rami S.
Essell, James
Lyons, Roger M.
Maris, Michael
DeZern, Amy E.
Sekeres, Mikkael A.
Roboz, Gail J.
BLOOD, 2015, 126 (23)
[7] A Phase II/III Trial of Oral Azacitidine (Oral-AZA) in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes (MDS)
Garcia-Manero, Guillermo
Santini, Valeria
Fenaux, Pierre
Suzuki, Takahiro
Sekeres, Mikkael A.
He, Jun
Barkalifa, Ronit
Vigil, Carlos E.
Prebet, Thomas
Komrokji, Rami
Giagounidis, Aristoteles
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S364 - S364
[8] Is there a role for ATRA in combination to EPO in lower risk myelodysplastic syndrome? Preliminary results of a phase II study.
Ades, L
Mohamed, H
Vassilief, D
Berger, E
Slama, B
Vey, N
Delarue, R
Beyne-Rauzy, O
Guerci, A
Cheze, S
Thomas, X
Stamatoullas, A
Gardembas, M
Bauduer, F
Kolb, A
Chaury, MC
Legros, L
Damaj, G
Hamza, F
Vaultier, S
Dreyfus, F
Fenaux, P
BLOOD, 2005, 106 (11) : 712A - 713A
[9] Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
Oliva, Esther Natalie
Riva, Marta
Niscola, Pasquale
Santini, Valeria
Breccia, Massimo
Giai, Valentina
Poloni, Antonella
Patriarca, Andrea
Crisa, Elena
Capodanno, Isabella
Salutari, Prassede
Reda, Gianluigi
Cascavilla, Nicola
Ferrero, Dario
Guarini, Attilio
Tripepi, Giovanni
Ianni, Giuseppe
Russo, Emilio
Castelli, Andrea
Fattizzo, Bruno
Beltrami, Germana
Bocchia, Monica
Molteni, Alfredo
Fenaux, Pierre
Germing, Ulrich
Ricco, Alessandra
Palumbo, Giuseppe A.
Impera, Stefana
Di Renzo, Nicola
Rivellini, Flavia
Buccisano, Francesco
Stamatoullas-Bastard, Aspasia
Liberati, Anna Marina
Candoni, Anna
Delfino, Ilaria Maria
Arcadi, Maria Teresa
Cufari, Patrizia
Rizzo, Lorenzo
Bova, Irene
D'Errigo, Maria Grazia
Zini, Gina
Latagliata, Roberto
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (28) : 4486 - +
[10] Addition of Lenalidomide (LEN) to Azacitidine (AZA) (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes (MDS): A Randomized Phase II Multicenter Study
Finelli, Carlo
Clissa, Cristina
Follo, Matilde Y.
Stanzani, Marta
Avanzini, Paolo
Bosi, Costanza
Castagnari, Barbara
Candoni, Anna
Crugnola, Monica
Giannini, Maria Benedetta
Gobbi, Marco
Leonardi, Giovanna
Rigolin, Gian Matteo
Tosi, Patrizia
Visani, Giuseppe
Cocco, Lucio
Cavo, Michele
Russo, Domenico
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →